by University of Oxford Credit: Pixabay/CC0 Public Domain A new study led by Oxford researchers has found vedolizumab can induce remission in patients who have chronic pouchitis after surgery for ulcerative colitis. Twelve percent of people with ulcerative colitis need surgery to have their colon removed (colectomy). Most of those have an ileo-anal pouch surgically constructed from...
Tag: <span>Vedolizumab</span>
Post
Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study
Liam Davenport July 11, 2022 When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab (Entyvio), suggests a Dutch registry study. Data on nearly 150 patients with UC who had already undergone treatment with anti-TNF drugs showed that combined clinical and biochemical remission was about five times more likely...